Highlights of weekly biotech stock moves

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) lost $0.21 to $6.41 last week after FDA's Oncologic Drugs Advisory Committee said it meet May 2 to discuss an NDA for Tivopath tivozanib to treat advanced renal cell carcinoma (RCC). The PDUFA date is July 28.

Biotie Therapies Corp. (HSE:BTH1V) was unchanged at €0.42 last week after the European Commission approved an MAA for Selincro nalmefene from partner H. Lundbeck A/S (CSE:LUN) to reduce alcohol consumption in adults with alcohol dependence. The company plans to launch mid-year...